GTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ZoomInfo Technologies (GTM) is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock is showing a modest pre-market uptick and the latest quarter improved, but analyst sentiment remains mostly cautious with repeated price target cuts and neutral-to-sell ratings. The technical setup is constructive but not decisive, and the options market is heavily bullish in positioning without a matching strong catalyst. My direct view: hold, not buy, for a long-term beginner at this time.
Current price is 6.3 in pre-market, up 0.80%. The MACD histogram is positive and expanding, which supports near-term bullish momentum. RSI_6 at 60.0 is neutral-to-slightly bullish and not overbought. Moving averages are converging, suggesting the stock is trying to stabilize rather than break out cleanly. Key levels: pivot 6.101, resistance 6.369 and 6.534, support 5.834 and 5.669. Overall, the trend is mildly positive but still lacks a strong confirmed uptrend.
["Q4 2025 revenue rose 3.24% YoY to $319.1M.", "Net income surged 137.67% YoY and EPS rose 175% YoY, showing meaningful bottom-line improvement.", "Gross margin improved to 82.36%, indicating strong profitability quality.", "Pre-market price is slightly higher, and MACD is turning positive.", "Options positioning is strongly bullish."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Analyst sentiment has weakened, with multiple target cuts across Barclays, Piper Sandler, Citi, RBC, UBS, and others.", "Several firms keep Neutral/Equal Weight/Hold or Sell-style views, suggesting limited upside conviction.", "Barclays specifically noted that meaningful software improvement may not arrive until the second half of 2026.", "No recent insider buying/selling trend and no congress trading data to signal strong external conviction."]
Latest reported quarter: 2025/Q4. Revenue increased to $319.1M, up 3.24% YoY, which shows modest growth. More importantly, profitability improved sharply: net income rose 137.67% YoY to $34.7M and EPS increased 175% YoY to $0.11. Gross margin also improved to 82.36%. The financial profile is improving, but revenue growth remains relatively slow for a long-term growth buy.
The recent analyst trend is clearly downward in price targets and mostly cautious in ratings. Barclays cut target to $8 and stayed Equal Weight; Piper Sandler cut to $7 and stayed Neutral; Citi cut to $5 and kept Sell; DA Davidson cut to $7 and stayed Neutral; RBC cut to $7 and kept Underperform; Morgan Stanley cut to $9 and kept Equal Weight; UBS cut to $8.50 and kept Neutral; Deutsche Bank cut to $10 and kept Hold. Wall Street pros see improving execution and margins, but they also see weak software sentiment, lack of near-term catalysts, and limited evidence of a durable top-line reacceleration. The cons view currently outweighs the bullish case.
